抗癌宝口服液治疗中晚期恶性肿瘤103例临床观察

目的：观察中药抗癌宝口服液治疗中晚期恶性肿瘤临床效果。方法：１０３例患者随机分为抗癌宝观察组与化疗对照组，对两组疗效作比较。结果：观察组患者免疫功能，近期有效率（ＣＲ＋ＰＲ），生存质量，１、２、３年生存期及中位生存时间，癌胚抗原下降水平，明显高于对照组，且有显著性差异。结论：抗癌宝具有抑制肿瘤生长，延长生存时间，提高生存质量之效。

Clinical study on effect of kang' aibao oral liquid in treating 103 malignant tumor patients]

OBJECTIVE: To observe the clinical efficacy of Kangaibao oral liquid(KABOL), a Chinese herbal preparation in treating malignant turmor of middle or advanced stage. METHODS: A comparative study was done by observing the effect of 103 patients treated with KABOL, and another 90 patients treated with chemotherapy in the same period were taken as a control group for comparison. RESULTS: The immunologic function, short-term effective rate (complete relieved rate and partial relieved rate), survival quality, 1-, 2- and 3-year survival rate, median suvival time, and the CEA declining rate of the KABOL group were significantly higher than those of the control group. CONCLUSIONS: KABOL has the effects of inhibiting tumor growth, prolonging the survival time and improving the quality of survival of tumor patient.